$AEMD Exosome Sciences, Inc., in collaboration wit

$AEMD Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc. (AEMD) and investigators at Boston University and the University of Washington, announced today the published preliminary results of possibly the first blood test to detect the neurodegenerative disease, Chronic Traumatic Encephalopathy (CTE) during life. An early online version of these findings has been published in the Journal of Alzheimer's Disease. CTE is associated with exposure to repetitive head impacts, such as those experienced by American football players, and can only be diagnosed post-mortem at this time. #CTE



http://stockpumpers.blogspot.com/2016/02/aeth...ences.html

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!